Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.44 |
| ▸ | BCHE | P06276 | 7/20 | 0.43 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3886612 | 0.81 | BCHE (0.49) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL3884177 | 0.78 | FFAR1 (0.43) | MAOBBCHECYP4F2CYP4A11MME | |
| SCHEMBL14021848 | 0.78 | CYP4F2 (0.52) | MAOBBCHECYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL4949899 | 0.77 | MAOB (0.47) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL14021492 | 0.76 | CYP4F2 (0.47) | MAOBBCHECYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL12017499 | 0.74 | NOS1 (0.49) | BCHEMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25480447 | 0.74 | MAOB (0.63) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL321092 | 0.74 | MAOB (0.62) | MAOBBCHECYP4F2CYP4A11MEN1 | |
| SCHEMBL1243217 | 0.73 | RAB9A (0.47) | MAOBMEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL9329311 | 0.73 | TAAR1 (0.48) | MAOBCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | claimed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | claimed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | claimed |
| EP-1511483-A4 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORP (US) | 2009-03-18 | — | — | EP | disclosed |
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060020036-A1 | Methods and compositions to promote bone homestasis | GALAPAGOS N.V. (BE) | 2006-01-26 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050171084-A1 | Methods of treatment with lxr modulators | SMITHKLINE BEECHAM CORPORATION | 2005-08-04 | — | — | US | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| EP-1511483-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-09 | — | — | EP | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003082198-A2 | METHODS OF TREATMENT WITH LXR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | MAOB 3322/4885BCHE 2160/4885CYP4F2 255/4885 |
| US-20050171084-A1 | Methods of treatment with lxr modulators | NR1H2, NR1H3, NR1H4 | MAOB 3738/4885BCHE 2442/4885CYP4F2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.